The Role of IGF-1R in Pediatric Malignancies

Overview

Journal Oncologist

Publisher Oxford University Press

Specialty Oncology

Date 2009 Jan 8

PMID 19126579

Citations 47

Authors

Su Young Kim

Jeffrey A Toretsky

Daniel Scher

Lee J Helman

Affiliations

Soon will be listed here.

Abstract

The insulin-like growth factor (IGF) family consists of ligands (IGF-I, IGF-II, insulin), several receptors (including IGF-1R), and six binding proteins (IGFBP-1 through IGFBP-6). Members of this family regulate key cellular activities and they also play an important role in the development and progression of both adult and childhood cancers. Binding of a ligand to the receptor leads to its activation, followed by signal transduction along several pathways. In some childhood malignancies, IGF-1R can be activated by endocrine, autocrine, or paracrine mechanisms. Although mutations in IGF-1R have not been identified, this signaling pathway is upregulated in many childhood cancers. These findings have led to the development of a host of IGF-1R signaling modulators that are currently being tested in clinical trials. This review explores the role of IGF-1R in a range of childhood malignancies.

Citing Articles

Receptor tyrosine kinases in breast cancer treatment: unraveling the potential.

Qi Y, Deng S, Wang K Am J Cancer Res. 2024; 14(9):4172-4196.

PMID: 39417188 PMC: 11477839. DOI: 10.62347/KIVS3169.

Modern treatment strategies in pediatric oncology and hematology.

Adamczewska-Wawrzynowicz K, Wiacek A, Kozlowska A, Mikosza K, Szefler L, Dudlik W Discov Oncol. 2023; 14(1):98.

PMID: 37314524 PMC: 10267092. DOI: 10.1007/s12672-023-00658-7.

The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models.

Hebron K, Wan X, Roth J, Liewehr D, Sealover N, Frye W Clin Cancer Res. 2022; 29(2):472-487.

PMID: 36322002 PMC: 9852065. DOI: 10.1158/1078-0432.CCR-22-1646.

Mini Review: Molecular Interpretation of the IGF/IGF-1R Axis in Cancer Treatment and Stem Cells-Based Therapy in Regenerative Medicine.

Lin S, Lin C, Lee W, Teng C, Shyu W, Jeng L Int J Mol Sci. 2022; 23(19).

PMID: 36233084 PMC: 9570316. DOI: 10.3390/ijms231911781.

An insulin growth factor-I/II-neutralizing monoclonal antibody in combination with epidermal growth factor receptor inhibitors potently inhibits tumor cell growth.

Ma G, Tan C, Shan Y, Shao N, Wang F, Dimitrov D J Cancer. 2022; 13(6):1830-1836.

PMID: 35399718 PMC: 8990425. DOI: 10.7150/jca.69064.

References

Yin D, Vreeland F, Schaaf L, Millham R, Duncan B, Sharma A . Clinical pharmacodynamic effects of the growth hormone receptor antagonist pegvisomant: implications for cancer therapy. Clin Cancer Res. 2007; 13(3):1000-9. DOI: 10.1158/1078-0432.CCR-06-1910. View

Toretsky J, Steinberg S, Thakar M, Counts D, Pironis B, Parente C . Insulin-like growth factor type 1 (IGF-1) and IGF binding protein-3 in patients with Ewing sarcoma family of tumors. Cancer. 2001; 92(11):2941-7. DOI: 10.1002/1097-0142(20011201)92:11<2941::aid-cncr10072>3.0.co;2-c. View

Butler A, Yakar S, Gewolb I, Karas M, Okubo Y, LeRoith D . Insulin-like growth factor-I receptor signal transduction: at the interface between physiology and cell biology. Comp Biochem Physiol B Biochem Mol Biol. 1999; 121(1):19-26. DOI: 10.1016/s0305-0491(98)10106-2. View

Romanus J, Helman L, Cooper M, Rechler M, Israel M . Autonomous growth of a human neuroblastoma cell line is mediated by insulin-like growth factor II. J Clin Invest. 1989; 84(3):829-39. PMC: 329726. DOI: 10.1172/JCI114243. View

Scotlandi K, Benini S, Nanni P, Lollini P, Nicoletti G, Landuzzi L . Blockage of insulin-like growth factor-I receptor inhibits the growth of Ewing's sarcoma in athymic mice. Cancer Res. 1998; 58(18):4127-31. View

Prieur A, Tirode F, Cohen P, Delattre O . EWS/FLI-1 silencing and gene profiling of Ewing cells reveal downstream oncogenic pathways and a crucial role for repression of insulin-like growth factor binding protein 3. Mol Cell Biol. 2004; 24(16):7275-83. PMC: 479730. DOI: 10.1128/MCB.24.16.7275-7283.2004. View

Adams T, Epa V, Garrett T, Ward C . Structure and function of the type 1 insulin-like growth factor receptor. Cell Mol Life Sci. 2000; 57(7):1050-93. PMC: 11146944. DOI: 10.1007/PL00000744. View

Rainier S, Johnson L, Dobry C, Ping A, Grundy P, Feinberg A . Relaxation of imprinted genes in human cancer. Nature. 1993; 362(6422):747-9. DOI: 10.1038/362747a0. View

Agaram N, LaQuaglia M, Ustun B, Guo T, Wong G, Socci N . Molecular characterization of pediatric gastrointestinal stromal tumors. Clin Cancer Res. 2008; 14(10):3204-15. PMC: 3805121. DOI: 10.1158/1078-0432.CCR-07-1984. View

10.

Janeway K, Liegl B, Harlow A, Le C, Perez-Atayde A, Kozakewich H . Pediatric KIT wild-type and platelet-derived growth factor receptor alpha-wild-type gastrointestinal stromal tumors share KIT activation but not mechanisms of genetic progression with adult gastrointestinal stromal tumors. Cancer Res. 2007; 67(19):9084-8. DOI: 10.1158/0008-5472.CAN-07-1938. View

11.

Yakar S, Wu Y, Setser J, Rosen C . The role of circulating IGF-I: lessons from human and animal models. Endocrine. 2003; 19(3):239-48. DOI: 10.1385/ENDO:19:3:239. View

12.

Khanna C, Prehn J, Hayden D, Cassaday R, Caylor J, Jacob S . A randomized controlled trial of octreotide pamoate long-acting release and carboplatin versus carboplatin alone in dogs with naturally occurring osteosarcoma: evaluation of insulin-like growth factor suppression and chemotherapy. Clin Cancer Res. 2002; 8(7):2406-12. View

13.

Bjornsson H, Brown L, Fallin M, Rongione M, Bibikova M, Wickham E . Epigenetic specificity of loss of imprinting of the IGF2 gene in Wilms tumors. J Natl Cancer Inst. 2007; 99(16):1270-3. PMC: 5533193. DOI: 10.1093/jnci/djm069. View

14.

Gray S, Eriksson T, Ekstrom C, Holm S, von Schweinitz D, Kogner P . Altered expression of members of the IGF-axis in hepatoblastomas. Br J Cancer. 2000; 82(9):1561-7. PMC: 2363389. DOI: 10.1054/bjoc.1999.1179. View

15.

Pollak M, Sem A, Richard M, Tetenes E, Bell R . Inhibition of metastatic behavior of murine osteosarcoma by hypophysectomy. J Natl Cancer Inst. 1992; 84(12):966-71. DOI: 10.1093/jnci/84.12.966. View

16.

Reeve A, Eccles M, Wilkins R, Bell G, Millow L . Expression of insulin-like growth factor-II transcripts in Wilms' tumour. Nature. 1985; 317(6034):258-60. DOI: 10.1038/317258a0. View

17.

Gallicchio M, Van Sinderen M, Bach L . Insulin-like growth factor binding protein-6 and CCI-779, an ester analogue of rapamycin, additively inhibit rhabdomyosarcoma growth. Horm Metab Res. 2004; 35(11-12):822-7. DOI: 10.1055/s-2004-814153. View

18.

OGorman D, Costello M, Weiss J, Firth S, Scott C . Decreased insulin-like growth factor-II/mannose 6-phosphate receptor expression enhances tumorigenicity in JEG-3 cells. Cancer Res. 1999; 59(22):5692-4. View

19.

Bach L, Headey S, Norton R . IGF-binding proteins--the pieces are falling into place. Trends Endocrinol Metab. 2005; 16(5):228-34. DOI: 10.1016/j.tem.2005.05.005. View

20.

Scotlandi K, Manara M, Nicoletti G, Lollini P, Lukas S, Benini S . Antitumor activity of the insulin-like growth factor-I receptor kinase inhibitor NVP-AEW541 in musculoskeletal tumors. Cancer Res. 2005; 65(9):3868-76. DOI: 10.1158/0008-5472.CAN-04-3192. View